Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Milvexian in Healthy Subjects
NCT02608970Phase 1Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2015
- Primary completion
- Jul 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in thrombosis comparing BMS-986177 with Placebo (2 arms). Primary endpoints: Safety of single dose of BMS-986177 at 3 days, Safety of multiple dose of BMS-986177 at 16 days and 2 more. Started Dec 2015; status: completed.
02
Drugs
milvexian
03
Conditions
thrombosis
Beyond the preview
Go deeper on NCT02608970.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02608970.